Form 4 for EW Edwards Lifesciences
Accepted 2023-05-09 00:00:00 ET · period of report 2023-05-07 · accession 0001225208-23-005616 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-05-09 | 2023-05-07+ | EW | Szyman Catherine M. | CVP, Critical Care | F - Tax | $88.74 | -3,530 | 28.5K | -11% | -$313.3K |
| DM | 2023-05-09 | 2023-05-07+ | EW | Szyman Catherine M. | CVP, Critical Care | M - OptEx | $33.14 | +80.3K | 104.1K | +337% | +$2.66M |
| D | 2023-05-09 | 2023-05-09 | EW | Szyman Catherine M. | CVP, Critical Care | S - Sale+OE | $88.94 | -75.6K | 28.5K | -73% | -$6.72M |
| DM | 2023-05-09 | 2023-05-07+ | EW | Szyman Catherine M. | CVP, Critical Care | M - OptEx | $0.00 | -80.3K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-07 | F | D | 2,154 | $88.74 | 29,906.78 | D | — | — | |
| 2 | Common | Common Stock | 2023-05-07 | M | A | 4,708 | $0.00 | 32,060.78 | D | — | — | (F1) On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. |
| 3 | Common | Common Stock | 2023-05-08 | F | D | 1,376 | $88.74 | 28,530.78 | D | — | — | |
| 4 | Common | Common Stock | 2023-05-09 | S | D | 75,600 | $88.94 | 28,530.78 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $88.35 to $89.14 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 5 | Common | Common Stock | 2023-05-09 | M | A | 75,600 | $35.20 | 104,130.78 | D | — | — | |
| 6 | Derivative | Performance Rights | 2023-05-07 | M | D | 4,708 | $0.00 | 1,292 | D | — · 2023-05-07 to 2027-05-06 | 4,708 Common Stock | (F1) On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. |
| 7 | Derivative | Employee Stock Option (Right to Acquire) | 2023-05-09 | M | D | 75,600 | $0.00 | 0 | D | $35.20 · 2017-05-12 to 2023-05-11 | 75,600 Common Stock |